An interventional study of Intervention in Relieves Vaginal Dryness / Improves Self-Lubrication, Improves Strength & Elasticity of Vagina (Aka Collagen and Elastin) and Improves Vaginal Wall Thickness, sponsored by NeuEve. Not yet recruiting at 1 site in United States. Open to female participants aged 55 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-26.
Sponsored by NeuEve · Not applicable, Interventional, and Treatment
This is a decentralized, single-group, open-label clinical trial evaluating a 12-week regimen of the NeuEve Dryness Treatment Kit (comprising Feminine Moisture Support oral softgels, Bone Support oral capsules, NeuEve Salve vulvar topical cream, NeuEve vaginal suppositories, and NeuEve Multivitamin) in postmenopausal women aged 55-65 who experience vaginal dryness, painful sex, and vaginal itching. The study aims to evaluate the effect of the kit on vaginal symptoms, vaginal pH, vaginal microbiome composition, sexual function, and quality of life over 12 weeks of use.
29 studies on the registry are indexed under Orgasm; 8 are open to participants now.
This study's planned enrollment of 40 is below the median of 80 across 20 interventional studies indexed under Orgasm.
Browse Orgasm studies →This is the only study on the registry with NeuEve as lead sponsor.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Female, aged 55-65 years at the time of consent. (defined as ≥12 consecutive months without menstrual bleeding, or surgical menopause). Currently experiencing self-reported vaginal dryness, painful sex (dyspareunia), and vaginal itching. Willing and able to use all five products of the NeuEve Dryness Treatment Kit as directed for 12 weeks. Willing to perform at-home vaginal pH testing and at-home vaginal microbiome sample collection. Willing to maintain current diet, sleep schedule, and physical activity level for the duration of the 12-week study. Willing to complete all study questionnaires via the Citruslabs platform. Resides in the United States with a deliverable shipping address.
Exclusion criteria:
Known allergy or to any ingredient in any component of the NeuEve Dryness Treatment Kit (including palm/coconut oil, beeswax, sea buckthorn, evening primrose, botanical extracts, or essential oils listed in the formulations). Currently pregnant, breastfeeding, or planning pregnancy during the study period. Self-reported diagnosed with or treated for a sexually transmitted infection (STI), pelvic inflammatory disease (PID), or a vaginal or urinary tract infection within the past 30 days. Current use of systemic or vaginal estrogen therapy, vaginal DHEA, or any other prescription treatment for vaginal dryness/GSM, unless on a stable regimen for ≥3 months and willing to maintain it without changes during the study (use of competing topical/vaginal moisturizers, lubricants, or suppositories during the study period is not permitted). History of gynecologic cancer (cervical, vaginal, vulvar, endometrial, or ovarian) within the past 2 years, or current active . Current participation in another interventional clinical study. Any medical condition that, in the opinion of the investigator, would compromise participant safety or the integrity of the study data. Planning to travel outside of the United States during the study duration.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Dietary Supplement: Intervention
All participants receive the five-component NeuEve Dryness Treatment Kit for 12 weeks: Feminine Moisture Support (1 softgel orally twice daily with meals); Bone Support (1 capsule orally twice daily with meals); NeuEve Salve (dime-sized amount applied topically to the vulva once daily at bedtime); NeuEve Silk Suppository (1 suppository inserted vaginally every other day at bedtime for Weeks 1-4) transitioning to NeuEve Silver Suppository (1 suppository inserted vaginally every 5 days for Weeks 5-12); and NeuEve Multivitamin (3 capsules daily with food, divided equally across the day).
Change in Vaginal Dryness
Change from Baseline to Week 12 in self-reported vaginal dryness assessed via a study-specific vaginal symptom questionnaire administered through the Citruslabs platform
Time frame: Baseline to Week 12
Change in Vaginal Itching
Change from Baseline to Week 12 in self-reported vaginal itching assessed via a study-specific vaginal symptom questionnaire administered through the Citruslabs platform
Time frame: Baseline to Week 12
Change in Vaginal Burning
Change from Baseline to Week 12 in self-reported vaginal burning assessed via a study-specific vaginal symptom questionnaire administered through the Citruslabs platform
Time frame: Baseline to Week 12
Change in Painful Sex (Dyspareunia)
Change from Baseline to Week 12 in self-reported painful sex assessed via a study-specific vaginal symptom questionnaire administered through the Citruslabs platform
Time frame: Baseline to Week 12
Change in Vaginal pH
Change from Baseline to Week 12 in vaginal pH measured by at-home vaginal pH test strips (self-administered)
Time frame: Baseline, Week 4, Week 8, and Week 12
Start is estimated for Sep 2026; primary completion for Dec 2026, 3 months later.
Of 14 interventional studies with no phase under Orgasm, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 13. This study's planned 3 months is below that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.